The numbers get worse each day as reports flood in of new cases from all over the world. Governments and health organizations are focused upon containment, mitigation, testing and treatment of the coronavirus pandemic. Large amounts of money have been devoted to finding a vaccine to this disease. As yet, little attention has been paid to potential treatments for sick people that are cheap, easy to mass manufacture and very safe such as vitamins D and C.
The Orthomolecular Medicine News Service, on Feb 21, 2020 makes the point very well:
“Medical orthodoxy obsessively focuses on searching for a vaccine and/or drug for coronavirus COVID-19). While they are looking for what would be fabulously profitable approaches, we have with vitamin C an existing, plausible, clinically demonstrated method to treat what coronavirus patients die from: severe acute respiratory syndrome, or pneumonia.’’
In a previous article I spoke about a 2017 study on the efficacy of vitamin D, which is actually a hormone, in giving people some protection against acute respiratory tract infections. Besides this vitamin/hormone another over looked potential treatment is high dose vitamin C.
Vitamin C as a potential treatment for the common cold and pneumonia has been demonized by the medical establishment since the pioneering work of Nobel Prize winner Linus Pauling in the early 1970s.
It is therefore very interesting to find out there are 3 clinical trials in China where vitamin C will be intravenously administered in high doses to patients with the coronavirus.
https://clinicaltrials.gov/ct2/show/NCT04264533
The study description reads:
“2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI.
Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections.
We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.’’
The lead clinician is ZhiYong Peng, Professor; Chief physician at Zhongnan Hospital of Wuhan University in the province of Hubei. We shall have to wait until September for these clinical trials to conclude. Hopefully they will have positive results to report and that vitamin C has helped save lives.
It would appear that some hospitals in China are already using high dose vitamin C therapy in conjunction with other treatments such as oxygen therapy and anti-virals. The second affiliated hospital of Xi’an Jiaotong University (Xibei Hospital) released a press statement on 21 February titled, ‘High-dose vitamin C treatment of new coronary pneumonia’. It noted the success of using high dose vitamin C early in the treatment of coronarvirus patients and explained its treatment protocol:
“On the afternoon of February 20, 2020, another 4 patients with severe neocoronary pneumonia recovered from the C10 West Ward of Tongji Hospital in the Tongji Hospital, which was taken over by the Second Aid National Medical Assistance Team of Xi'an Jiaotong University. The medical team was officially put into work In the past 8 patients have been discharged from hospital.
After 10 days of practical exploration by the medical team and repeated discussions by the expert group, our expert group proposed a specific plan for the combination of high-dose vitamin C to treat the new crown, and achieved good results in clinical applications. Our treatment plan is generally summarized as "early, adequate, short course, combined."
Early stage: The so-called "early stage" refers to the timely application of high-dose vitamin C in the early stages of the disease course.
We believe that for patients with severe neonatal pneumonia and critically ill patients, vitamin C treatment should be initiated as soon as possible after admission. This is because no matter the past Keshan disease, SARS and Middle East respiratory syndrome, or the current new pneumonia, the main cause of death of patients is cardiopulmonary failure caused by increased acute oxidative stress.
When the virus causes increased oxidative stress in the body and increased capillary permeability, early application of large doses of vitamin C can have a strong antioxidant effect, reduce inflammatory responses, and improve endothelial function.
Adequate: Adequate refers to the large amount of vitamin C. Numerous studies have shown that the dose of vitamin C has a lot to do with the effect of treatment Our past experience in successfully rescuing acute Keshan disease and current studies at home and abroad show that high-dose vitamin C can not only improve antiviral levels, but more importantly, can prevent and treat acute lung injury (ALI) and acute respiratory distress (ARDS).
Short-term: Short-term means that the medication time does not exceed 1 week.Short-term application of large doses of vitamin C in the critical period of disease progression can achieve twice the result with half the effort, and can significantly reduce the side effects such as kidney stones, hematuria and renal colic that should be brought in the long term, reduce nausea, vomiting, hypotension, tachycardia, etc Adverse reactions to avoid the body's dependence on exogenous vitamin C caused by long-term medication.’’
http://2yuan.xjtu.edu.cn/Html/News/Articles/21774.html
Meanwhile, the government of Shanghai has adopted mega dose vitamin C therapy into its coronavirus treatment protocol. This protocol was adopted on 1 March. See below.
In the treatment plan section of the document it notes that anti-virals should be used in conjunction with oxygen therapy. It states that to prevent a coronavirus patient becoming a severe case then:
“Heparin anticoagulation and high-dose vitamin C are recommended. Low-molecular-weight heparin 1 to 2 per day, continued until the patient's D-dimer level returned to normal. Once fibrinogen degradation product (FDP) ≥10 µg / mL and / or D-dimer ≥5 μg / mL, switch to unfractionated heparin. Vitamin C is administered at a dose of 50 to 100 mg / kg per day, and the continuous use time is aimed at a significant improvement in the oxygenation index. ‘’
If a patient becomes critically ill it recommends a variety of measures including:
“Prevention and treatment of cytokine storm: large doses of vitamin C and unfractionated heparin are recommended. Large doses of vitamin C are injected intravenously at a dose of 100 to 200 mg / kg per day. The duration of continuous use is aimed at a significant improvement in the oxygenation index. The use of large doses is recommended.’’
https://mp.weixin.qq.com/s/bF2YhJKiOfe1yimBc4XwOA
The protocol mentions the grave dangers posed by sepsis to critically ill patients.
In the United States recent work by Dr. Paul Marik et al have demonstrated the efficacy of high dose vitamin C in successful treating sepsis which poses a danger to many pneumonia patients.
In the Chest Journal June 2017 Volume 151, Issue 6, Pages 1229–1238, Dr, Marik et al published an article,”Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock’’.
It’s conclusions were very clear:
“Our results suggest that the early use of intravenous vitamin C, together with corticosteroids and thiamine, are effective in preventing progressive organ dysfunction, including acute kidney injury, and in reducing the mortality of patients with severe sepsis and septic shock. Additional studies are required to confirm these preliminary findings.’’
In response to criticism of his study Dr. Marik issued a rebuttal in the same journal that noted:
“IV vitamin C has been successfully used to treat patients in the general surgical ICU4; patients with traumatic injuries5, 6; and patients with sepsis,7, 8 pancreatitis,9 burns,10, 11 and tetanus12; as well as patients undergoing coronary artery bypass surgery.13 No adverse effects of IV vitamin C were noted in any of these studies. Patients with malignancy have received adjunctive treatment with IV vitamin C in doses of up to 150 g (100 times the dose that we recommend) without untoward side effects. We therefore believe that the administration of vitamin C in the dosage that we recommend is an exceedingly safe intervention.’’
Marik et al, Chest Journal, October 2017 Volume 152, Issue 4, Pages 905–906.
As the global pandemic gathers momentum we can only hope that public health authorities outside of China will consider using vitamin C therapy as a supplement to more mainstream treatments.
The Orthomolecular Medicine News Service, on Feb 21, 2020 makes the point very well:
“Medical orthodoxy obsessively focuses on searching for a vaccine and/or drug for coronavirus COVID-19). While they are looking for what would be fabulously profitable approaches, we have with vitamin C an existing, plausible, clinically demonstrated method to treat what coronavirus patients die from: severe acute respiratory syndrome, or pneumonia.’’
In a previous article I spoke about a 2017 study on the efficacy of vitamin D, which is actually a hormone, in giving people some protection against acute respiratory tract infections. Besides this vitamin/hormone another over looked potential treatment is high dose vitamin C.
Vitamin C as a potential treatment for the common cold and pneumonia has been demonized by the medical establishment since the pioneering work of Nobel Prize winner Linus Pauling in the early 1970s.
It is therefore very interesting to find out there are 3 clinical trials in China where vitamin C will be intravenously administered in high doses to patients with the coronavirus.
https://clinicaltrials.gov/ct2/show/NCT04264533
The study description reads:
“2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI.
Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections.
We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.’’
The lead clinician is ZhiYong Peng, Professor; Chief physician at Zhongnan Hospital of Wuhan University in the province of Hubei. We shall have to wait until September for these clinical trials to conclude. Hopefully they will have positive results to report and that vitamin C has helped save lives.
It would appear that some hospitals in China are already using high dose vitamin C therapy in conjunction with other treatments such as oxygen therapy and anti-virals. The second affiliated hospital of Xi’an Jiaotong University (Xibei Hospital) released a press statement on 21 February titled, ‘High-dose vitamin C treatment of new coronary pneumonia’. It noted the success of using high dose vitamin C early in the treatment of coronarvirus patients and explained its treatment protocol:
“On the afternoon of February 20, 2020, another 4 patients with severe neocoronary pneumonia recovered from the C10 West Ward of Tongji Hospital in the Tongji Hospital, which was taken over by the Second Aid National Medical Assistance Team of Xi'an Jiaotong University. The medical team was officially put into work In the past 8 patients have been discharged from hospital.
After 10 days of practical exploration by the medical team and repeated discussions by the expert group, our expert group proposed a specific plan for the combination of high-dose vitamin C to treat the new crown, and achieved good results in clinical applications. Our treatment plan is generally summarized as "early, adequate, short course, combined."
Early stage: The so-called "early stage" refers to the timely application of high-dose vitamin C in the early stages of the disease course.
We believe that for patients with severe neonatal pneumonia and critically ill patients, vitamin C treatment should be initiated as soon as possible after admission. This is because no matter the past Keshan disease, SARS and Middle East respiratory syndrome, or the current new pneumonia, the main cause of death of patients is cardiopulmonary failure caused by increased acute oxidative stress.
When the virus causes increased oxidative stress in the body and increased capillary permeability, early application of large doses of vitamin C can have a strong antioxidant effect, reduce inflammatory responses, and improve endothelial function.
Adequate: Adequate refers to the large amount of vitamin C. Numerous studies have shown that the dose of vitamin C has a lot to do with the effect of treatment Our past experience in successfully rescuing acute Keshan disease and current studies at home and abroad show that high-dose vitamin C can not only improve antiviral levels, but more importantly, can prevent and treat acute lung injury (ALI) and acute respiratory distress (ARDS).
Short-term: Short-term means that the medication time does not exceed 1 week.Short-term application of large doses of vitamin C in the critical period of disease progression can achieve twice the result with half the effort, and can significantly reduce the side effects such as kidney stones, hematuria and renal colic that should be brought in the long term, reduce nausea, vomiting, hypotension, tachycardia, etc Adverse reactions to avoid the body's dependence on exogenous vitamin C caused by long-term medication.’’
http://2yuan.xjtu.edu.cn/Html/News/Articles/21774.html
Meanwhile, the government of Shanghai has adopted mega dose vitamin C therapy into its coronavirus treatment protocol. This protocol was adopted on 1 March. See below.
In the treatment plan section of the document it notes that anti-virals should be used in conjunction with oxygen therapy. It states that to prevent a coronavirus patient becoming a severe case then:
“Heparin anticoagulation and high-dose vitamin C are recommended. Low-molecular-weight heparin 1 to 2 per day, continued until the patient's D-dimer level returned to normal. Once fibrinogen degradation product (FDP) ≥10 µg / mL and / or D-dimer ≥5 μg / mL, switch to unfractionated heparin. Vitamin C is administered at a dose of 50 to 100 mg / kg per day, and the continuous use time is aimed at a significant improvement in the oxygenation index. ‘’
If a patient becomes critically ill it recommends a variety of measures including:
“Prevention and treatment of cytokine storm: large doses of vitamin C and unfractionated heparin are recommended. Large doses of vitamin C are injected intravenously at a dose of 100 to 200 mg / kg per day. The duration of continuous use is aimed at a significant improvement in the oxygenation index. The use of large doses is recommended.’’
https://mp.weixin.qq.com/s/bF2YhJKiOfe1yimBc4XwOA
The protocol mentions the grave dangers posed by sepsis to critically ill patients.
In the United States recent work by Dr. Paul Marik et al have demonstrated the efficacy of high dose vitamin C in successful treating sepsis which poses a danger to many pneumonia patients.
In the Chest Journal June 2017 Volume 151, Issue 6, Pages 1229–1238, Dr, Marik et al published an article,”Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock’’.
It’s conclusions were very clear:
“Our results suggest that the early use of intravenous vitamin C, together with corticosteroids and thiamine, are effective in preventing progressive organ dysfunction, including acute kidney injury, and in reducing the mortality of patients with severe sepsis and septic shock. Additional studies are required to confirm these preliminary findings.’’
In response to criticism of his study Dr. Marik issued a rebuttal in the same journal that noted:
“IV vitamin C has been successfully used to treat patients in the general surgical ICU4; patients with traumatic injuries5, 6; and patients with sepsis,7, 8 pancreatitis,9 burns,10, 11 and tetanus12; as well as patients undergoing coronary artery bypass surgery.13 No adverse effects of IV vitamin C were noted in any of these studies. Patients with malignancy have received adjunctive treatment with IV vitamin C in doses of up to 150 g (100 times the dose that we recommend) without untoward side effects. We therefore believe that the administration of vitamin C in the dosage that we recommend is an exceedingly safe intervention.’’
Marik et al, Chest Journal, October 2017 Volume 152, Issue 4, Pages 905–906.
As the global pandemic gathers momentum we can only hope that public health authorities outside of China will consider using vitamin C therapy as a supplement to more mainstream treatments.